Global advancements in pharmaceuticals and biotechnology are accelerating like never before. This has led to unprecedented M&A and funding activity as we race to develop medicines, therapies, and devices aimed at improving well-being and confronting health threats, both old and new. Life sciences investment banking requires experienced and nimble financial management.
Not surprisingly, 2020 saw a record number of biotech industry IPOs raise $13.5 billion.* Quoin provides comprehensive advisory and financing capabilities to support our clients who innovate businesses in the specialty pharmaceutical, generic pharmaceutical and biotechnology sectors, domestically and throughout EMEA and BRIC nations.
(* Source: BioSpace)
With the increased focus on Environmental, Social and Governance (ESG) criteria, clients can leverage the advice of Quoin’s experienced Sustainability & Renewable Energy team.